Albany, New York, September 18, 2017: Currently, considering the worldwide condition, the rise of lifestyle diseases such as diabetes and other chronic ailments are spotted as the superior cause of obesity. Moreover, it has been noted that geriatric people are far more prone to conceal sarcopenia, known as a noticeable rise in body fat. All of these factors call out for the need of obesity management, which is carefully studied through a smart report added to the wide repository of Market Research Reports Search Engine (MRRSE). This research report is titled “Obesity Management Market: Global Industry Analysis and Opportunity Assessment 2017-2027”, which encloses details about the current as well as future market status until 2027. Furthermore, latest trends, innovations, and market dynamics are also studied in this report.
As per research findings, more than half a billion people were found to be obese in 2014, and almost 2 billion adults were tagged as overweight. Such statistics are found to be alarming and requires serious obesity management measures on a global level. This report initiates with a thorough analysis of the market based on factors such as market size (US$ Mn), Y-o-Y growth and Absolute $ Opportunity for the period until 2027. This section also comprises facets such as market drivers, restraints, and opportunities in the global obesity management market.
The next section discusses the market segmentation in the global obesity management market. On the basis of drug type, the market covers bupropion and naltrexone, phentermine and topiramate, orlistat, lorcaserin and liraglutide. Based on surgery type, duodenal switch surgery, gastric bypass surgery, adjustable gastric banding surgery and gastric sleeve surgery are marked as the prime segments.
Geographically, the global market for obesity management is bifurcated across North America, Western Europe, Eastern Europe, Latin America, APEJ, Japan, and MEA. Each of these mentioned regions is studied on the basis of elements like BPS analysis, Y-o-Y growth, and market value forecast. According to this informative report, the North America region is forecasted to account for more than 1/3rd revenue share of the global obesity management market in 2017. By 2027, the region is anticipated to gain a substantial 224 BPS. Further, the Bupropion and Naltrexone drug segment in the North American market for obesity management is estimated to acquire a worth of US$ 13.6 Mn in 2017, and further rise to reach a mark slightly under US$ 32 Mn by 2027.
Browse Full Global Obesity Management Market Report with TOC : http://www.mrrse.com/obesity-management-market
Market Research Reports Search Engine (MRRSE) is an industry-leading database of market intelligence reports. MRRSE is driven by a stellar team of research experts and advisors trained to offer objective advice. Our sophisticated search algorithm returns results based on the report title, geographical region, publisher, or other keywords.
MRRSE partners exclusively with leading global publishers to provide clients single-point access to top-of-the-line market research. MRRSE’s repository is updated every day to keep its clients ahead of the next new trend in market research, be it competitive intelligence, product or service trends or strategic consulting.
90, State Street
Albany, NY – 12207